Novo Nordisk reports positive weekly growth hormone data

A phase III study has demonstrated that Sogroya, a weekly injection, works as well as daily drug Norditropin to treat children with growth hormone deficiency.

Photo: Novo Nordisk / PR

Novo Nordisk has presented positive results from a phase III trial of its treatment for children with growth hormone deficiency, dubbed Sogroya, according to a company press release.

The data was made public today in connection with the Endocrine Society’s annual meeting, ENDO 2022, which is taking place in Georgia, US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs